Cumberland Pharma's Q2 revenue rises 10% yr/yr

Cumberland Pharmaceuticals

05/08/2025 22:02

Overview

Cumberland Q2 2025 revenue rises 10% yr/yr to $10.8 mln

Year-to-date revenue up 23% over first half of 2024

Co announces Vibativ 4-Vial Starter Pak availability through Vizient

Outlook

Company expresses optimism for continued success in clinical programs

Cumberland optimistic about building on first-half success

Result Drivers

PRODUCT PORTFOLIO - FDA-approved brands contributed to a 10% revenue increase in Q2 2025

VIBATIV AVAILABILITY - New supply arrangement with Vizient enhances Vibativ treatment flexibility

CLINICAL PROGRESS - Phase II FIGHT DMD trial shows promising results for ifetroban in improving cardiac function

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
$10.80 mln
Q2 Operating Expenses
$11.60 mln


Analyst Coverage

The one available analyst rating on the shares is "hold"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Press Release: ID:nPn3qxwh8a

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)